GPRC6A Functionality in the Cow: Evidence from Dietary Arginine Supplementation in Early-Lactating Dairy Cows

A useful question in livestock functional genomics is whether a receptor is merely annotated in the bovine genome or whether it participates in real physiological processes in the cow. For GPRC6A, a nutrient-sensing G protein-coupled receptor, a 2025 article in Animal Nutrition adds an important in vivo layer to the evidence.

The study is titled:

“Impacts of dietary arginine supplementation on performance, nutrient digestion and expression of proteins related to milk fatty acid and casein synthesis in early lactating dairy cows.”

The authors are Jing Zhang, Jiaojiao Lang, Lijun Bu, Yapeng Liu, Wenjie Huo, Caixia Pei, and Qiang Liu, from the College of Animal Science, Shanxi Agricultural University, Taigu, Shanxi, China. The paper was published in Animal Nutrition volume 21, pages 267 to 278, in 2025. The article was received on 24 May 2024, revised on 28 August 2024, accepted on 28 October 2024, and made available online on 7 April 2025.

The key question of the paper is whether rumen-protected arginine, abbreviated RPArg, can improve milk production, milk fatty acid synthesis, milk protein synthesis, and mammary gland development in early-lactating dairy cows. For GPRC6A biology, the important part is that the authors measure GPRC6A protein expression in bovine mammary gland tissue and place it upstream of Akt/mTOR signaling.

The evidence supports the following model:

Dietary RPArg → increased mammary GPRC6A protein → Akt/mTOR activation → mammary cell proliferation and biosynthetic activity → increased milk, milk fat, and milk protein outputs

This is not as mechanistically direct as a GPRC6A knockdown experiment. Still, it is valuable because it is conducted in live dairy cows, not only in cultured cells.

1. The study is directly bovine and directly physiological

The first strength of this paper is that it works in actual lactating cows.

The authors used 48 multiparous Chinese Holstein dairy cows. The cows were early in lactation, with an average milk yield of about 34.9 kg/day, body weight around 658 kg, and days in lactation around 16.4 days.

The cows were assigned to four groups:

• Control: no RPArg
• Low RPArg: 20 g/day arginine
• Medium RPArg: 40 g/day arginine
• High RPArg: 60 g/day arginine

The experiment lasted 95 days, including a covariate period, adaptation period, and sampling period.

That design is important. The study is not simply asking whether arginine changes signaling in a dish. It asks whether dietary arginine supplementation changes milk production and mammary gland molecular biology in the cow.

The authors state that their goal was to test whether RPArg could enhance lactation performance, milk fatty acid synthesis, and milk protein synthesis by promoting mammary gland development and the expression of related proteins.

2. RPArg increases milk production and milk-component yields

The first functional layer is the whole-animal phenotype.

The paper reports that dry matter intake was not significantly changed by RPArg. However, milk output increased.

The authors state that actual milk, 4% fat-corrected milk, energy-corrected milk, milk fat, and milk protein increased linearly with RPArg supplementation.

This matters because a receptor-signaling argument is stronger when the molecular pathway is connected to a real physiological output. Here, the output is not abstract. It is milk production.

The core production phenotype is:

More RPArg → more milk, more milk fat yield, more milk protein yield

This establishes that dietary arginine is doing something biologically meaningful in early-lactating cows.

3. RPArg shifts milk fatty-acid production toward mammary de novo fatty-acid synthesis

The second functional layer is milk fatty-acid composition.

The paper reports that RPArg linearly increased the production of de novo fatty acids and mixed-source fatty acids, while reducing preformed fatty acids.

This is a biologically important pattern. In dairy biology, de novo fatty acids are synthesized in the mammary gland. Therefore, increased de novo fatty-acid yield is consistent with increased mammary lipogenic activity.

The table evidence is particularly relevant:

• De novo fatty acids increased from 329.1 g/day in control cows to 408.3 g/day in the medium RPArg group.
• Mixed-source fatty acids increased from 404.0 g/day to 451.8 g/day.
• Preformed fatty acids decreased from 503.9 g/day to 478.3 g/day in the medium RPArg group.

This supports the idea that RPArg affects mammary metabolism, not only total milk volume.

4. Figure 2 directly links RPArg to bovine mammary GPRC6A protein

The most important figure for GPRC6A is Figure 2.

Figure 2 is titled:

“Effects of dietary medium rumen-protected arginine (MRPArg) addition on the Akt-mTOR signaling pathway in bovine mammary glands.”

The figure contains two parts:

Figure 2A: Western blot evidence

Figure 2A shows Western blots for:

• GPRC6A
• Akt
• p-Akt
• mTOR
• p-mTOR
• β-actin

The comparison is between:

• Control cows receiving 0 g/day arginine
• MRPArg cows receiving 40 g/day arginine

The figure shows stronger GPRC6A signal in the MRPArg group, alongside stronger p-Akt and p-mTOR signaling.

Figure 2B: Quantification

Figure 2B quantifies the immune-positive bands for:

• GPRC6A
• p-Akt/Akt
• p-mTOR/mTOR

The bar plot shows that all three are significantly increased in the MRPArg group. The figure caption marks significance at P < 0.01 versus control.

This is the central bovine GPRC6A evidence in the paper.

It shows that dietary arginine supplementation in live cows is associated with increased GPRC6A protein expression in mammary gland tissue and activation of downstream Akt/mTOR signaling.

5. The Results section explicitly states that GPRC6A and Akt/mTOR increased

The Results section gives a direct textual statement corresponding to Figure 2.

The authors report that protein expression levels of GPRC6A, p-Akt/Akt, and p-mTOR/mTOR increased with arginine provision.

This is important because Figure 2 is not an isolated image. The text and quantification interpret the Western blot as a significant increase in GPRC6A-associated signaling.

From a functionality standpoint, this suggests that bovine GPRC6A is responsive to arginine nutrition in mammary tissue and is coupled to a plausible intracellular signaling pathway.

6. Figure 1 shows the mammary-development phenotype that Akt/mTOR could explain

If GPRC6A activates Akt/mTOR, one expected outcome is increased cell proliferation and reduced apoptosis.

That is exactly what the paper tests in Figure 1.

Figure 1 is titled:

“Effects of dietary medium rumen-protected arginine addition on proliferation-related protein expressions in bovine mammary glands.”

Figure 1A

The Western blot includes:

• PCNA
• Cyclin D1
• BCL2
• BAX
• caspase-3
• caspase-9
• β-actin

Figure 1B

The quantification shows that MRPArg increases proliferation and survival markers, while decreasing apoptosis markers.

The Results section reports that 40 g/day arginine as RPArg increased Cyclin D1, PCNA, BCL2, and BCL2/BAX, while decreasing BAX, caspase-3, and caspase-9.

This supports the model that RPArg promotes mammary gland development by stimulating mammary epithelial proliferation and suppressing apoptosis.

The connection to GPRC6A is indirect but biologically coherent:

GPRC6A increase + Akt/mTOR activation + proliferation marker increase = plausible receptor-linked mammary growth response

7. Figure 3 connects the pathway to milk-fat synthesis

The next downstream layer is milk-fat synthesis.

Figure 3 is titled:

“Effects of dietary medium rumen-protected arginine addition on the expressions of proteins related to fatty acid synthesis in bovine mammary glands.”

Figure 3A

The Western blot includes:

• AMPK
• p-AMPK
• PPARγ
• SREBP1
• ACACA
• p-ACACA
• FASN
• SCD1
• β-actin

Figure 3B

The quantification shows increased protein expression of lipogenic regulators and enzymes, including:

• PPARγ
• SREBP1
• p-ACACA/ACACA
• FASN
• SCD1

It also shows reduced p-AMPK/AMPK.

This is important because SREBP1, ACACA, FASN, and SCD1 are central to fatty-acid synthesis and desaturation in mammary tissue.

The Results section states that supplementation with 40 g/day arginine increased PPARG, SREBP1, FASN, and SCD1 and promoted ACACA phosphorylation.

That gives a molecular explanation for the milk fatty-acid data.

The logic becomes:

RPArg → GPRC6A/Akt/mTOR → lipogenic protein expression → increased de novo and mixed-source fatty-acid yields

Again, the paper does not prove that every step is GPRC6A-dependent, but the molecular pattern supports functionality.

8. Figure 4 connects RPArg to milk-protein synthesis

The paper also tests milk-protein signaling.

Figure 4 is titled:

“Effects of dietary medium rumen-protected arginine addition on the expressions of proteins related to milk protein synthesis in bovine mammary glands.”

Figure 4A

The Western blot includes:

• JAK2
• p-JAK2
• STAT5
• p-STAT5
• αs1-casein
• β-casein
• κ-casein
• β-actin

Figure 4B

The quantification shows increased casein proteins and increased phosphorylation ratios for JAK2 and STAT5.

The Results section reports that the 40 g/day RPArg group significantly increased κ-casein, β-casein, and αs1-casein. It also reports higher p-JAK2/JAK2 and p-STAT5/STAT5.

This part is not specifically GPRC6A-centered, but it strengthens the broader physiological argument: RPArg supplementation activates mammary biosynthetic pathways that match the increased milk protein phenotype.

9. The Discussion directly interprets the GPRC6A-Akt/mTOR axis

The Discussion is where the authors explicitly connect the observed bovine GPRC6A increase to arginine signaling.

They write that GPRC6A links arginine with the AKT/mTOR pathway and discuss previous work showing that GPRC6A knockdown inhibits arginine activation of Akt signaling in mammary epithelial cells.

Then the authors make the bovine-specific interpretation:

“Arg addition enhanced the protein expressions of GPRC6A” and stimulated Akt/mTOR phosphorylation.

They further state that arginine affects the AKT-mTOR pathway by activating GPRC6A and regulates bovine mammary epithelial cell proliferation.

This is the strongest interpretive claim in the paper.

It turns the Figure 2 observation into a proposed pathway:

Arginine → GPRC6A activation → Akt/mTOR phosphorylation → mammary epithelial proliferation and biosynthesis

10. The Conclusion explicitly names the GPRC6A-Akt/mTOR pathway

The conclusion is also direct.

The authors conclude that RPArg supplementation activates the GPRC6A-Akt/mTOR signal pathway and promotes proteins connected with cell proliferation, milk fatty-acid synthesis, and milk protein synthesis.

That final statement is important because the authors are not merely saying that GPRC6A changed. They are presenting GPRC6A-Akt/mTOR as part of the mechanism by which RPArg improves mammary function.

11. What this paper proves, and what it does not prove

This paper provides meaningful bovine-specific evidence for GPRC6A functionality, but the strength of evidence should be classified carefully.

What it supports strongly

The study supports that, in lactating dairy cows:

1. RPArg increases milk, milk fat, and milk protein yields.
2. RPArg increases de novo and mixed-source milk fatty-acid yields.
3. RPArg increases mammary GPRC6A protein expression.
4. RPArg increases Akt and mTOR phosphorylation.
5. RPArg increases mammary proliferation markers.
6. RPArg increases mammary lipogenic proteins.
7. RPArg increases casein-related protein expression.
8. The authors interpret these effects through a GPRC6A-Akt/mTOR signaling model.

What it does not directly prove

The study does not include:

• GPRC6A knockdown in bovine mammary tissue
• GPRC6A knockout
• GPRC6A antagonist treatment
• GPRC6A rescue experiment
• direct arginine-GPRC6A binding assay
• immunofluorescence localization of GPRC6A
• receptor-specific cAMP, calcium, β-arrestin, or ERK activation assay

Therefore, the safest conclusion is not that this paper alone proves direct arginine-GPRC6A signaling in cows. Rather, it shows that dietary arginine supplementation in live cows increases mammary GPRC6A protein together with Akt/mTOR activation and milk-biosynthesis outputs.

12. Why this matters for bovine GPRC6A functionality

This paper is valuable because it moves the GPRC6A discussion from cultured cells into the whole animal.

Previous bovine mammary epithelial cell studies provided stronger causal evidence using GPRC6A knockdown. This 2025 dairy cow study adds in vivo support: when arginine is supplied to live cows in a rumen-protected form, mammary gland tissue shows increased GPRC6A protein and increased Akt/mTOR signaling, while milk yield, milk fat yield, milk protein yield, and mammary biosynthetic proteins also increase.

The most balanced interpretation is:

GPRC6A in cattle is supported by both cell-level causal evidence and whole-animal nutritional evidence. This article contributes the whole-animal layer: dietary arginine supplementation is associated with activation of a mammary GPRC6A-Akt/mTOR axis in early-lactating dairy cows.

In short, this paper does not stand alone as a definitive receptor-mechanism study, but it strongly supports the idea that bovine GPRC6A is part of a functional nutrient-responsive mammary signaling network.

GPRC6A: The Receptor That Tried to Explain Everything

 

How a Little-Known GPCR Became One of the Most Controversial Receptors in Endocrinology

In molecular biology, there are receptors that quietly perform their jobs for decades. Then there are receptors that seem to promise a grand unified theory of physiology.

GPRC6A belongs firmly in the second category.

Over the past two decades, this obscure member of the Class C G-protein coupled receptor family has been proposed as:

• An amino acid sensor
• A calcium sensor
• A receptor for osteocalcin
• A receptor for testosterone
• A regulator of insulin secretion
• A regulator of testosterone production
• A mediator of exercise adaptation
• A contributor to metabolic syndrome
• A participant in prostate cancer progression

At various times, it has been described as a master regulator of metabolism, a key endocrine hub, and by its critics, a receptor whose importance may have been greatly overstated.

The history of GPRC6A is therefore not merely a story about a receptor. It is a case study in how scientific ideas emerge, expand, encounter contradictory evidence, and ultimately evolve.

---

Act I (2004–2008): The Discovery Years

The first phase of GPRC6A research was relatively straightforward.

Researchers studying orphan GPCRs identified GPRC6A as a novel member of the same family that includes the calcium-sensing receptor and glutamate receptors.

Early studies focused on answering a simple question:

What activates this receptor?

The leading contributors during this period were researchers such as Hans Bräuner-Osborne, Petrine Wellendorph, and colleagues in Copenhagen.

Landmark Findings

The receptor responds to amino acids

Studies demonstrated activation by basic amino acids such as:

• L-arginine
• L-lysine
• L-ornithine

This immediately suggested a role in nutrient sensing.

The receptor responds to cations

Calcium and other divalent ions also influenced receptor activity.

This combination of amino-acid sensing and cation sensing made GPRC6A biologically intriguing.

At this stage, however, few researchers would have predicted that the receptor would soon become central to debates involving diabetes, fertility, cancer, and endocrinology.

---

Act II (2009–2015): The Quarles Revolution

Every scientific field eventually acquires a dominant narrative.

For GPRC6A, that narrative was largely created by the research program led by Min Pi and L. Darryl Quarles at the University of Tennessee.

Their work transformed GPRC6A from an amino-acid sensor into a potential master regulator of whole-body metabolism.

Influential Paper #1

Pi M., Quarles LD. (2012)

"Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks."

Impact:

• Proposed GPRC6A as a multi-ligand receptor.
• Suggested that one receptor integrates signals from amino acids, osteocalcin, testosterone, and cations.
• Introduced the idea that GPRC6A coordinates communication among multiple organs.

This paper fundamentally changed how the field viewed the receptor.

---

Influential Paper #2

Pi M., Wu Y., Quarles LD. (2011)

"GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo."

Impact:

• Proposed that osteocalcin directly signals through GPRC6A.
• Linked bone biology to pancreatic insulin secretion.
• Helped establish the emerging concept of bone as an endocrine organ.

This work would become one of the foundational pillars of the osteocalcin-GPRC6A hypothesis.

---

Influential Paper #3

Pi M. et al. (2012)

"GPRC6A mediates the effects of L-arginine on insulin secretion."

Impact:

• Connected nutrient sensing directly to insulin secretion.
• Reinforced the idea that GPRC6A influences metabolic regulation.

---

Act III: The Karsenty Connection

While Quarles and colleagues expanded GPRC6A biology, another influential group was simultaneously revolutionizing endocrinology.

The laboratory of Gerard Karsenty and Patricia Ducy at Columbia University developed the concept that bone functions as an endocrine organ.

Osteocalcin became the centerpiece of this new framework.

Influential Paper #4

Wei J., Hanna T., Suda N., Karsenty G., Ducy P. (2014)

"Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a."

Impact:

• Demonstrated that osteocalcin influences pancreatic β-cells through GPRC6A.
• Strengthened the proposed bone-pancreas endocrine axis.
• Became one of the most cited studies linking skeletal biology to metabolism.

Together, the Karsenty and Quarles groups created a powerful narrative:

Bone releases osteocalcin → osteocalcin activates GPRC6A → insulin and testosterone production increase → metabolism improves.

For several years this framework dominated the field.

---

Act IV: Expansion into Multiple Organ Systems

Once GPRC6A was proposed as a metabolic regulator, researchers began looking everywhere.

Remarkably, evidence accumulated for roles in:

Intestine

Mizokami et al. (2013)

Showed that osteocalcin stimulates GLP-1 secretion, providing a potential mechanism linking bone signals to glucose regulation.

Muscle

Mera et al. (2016)

Demonstrated that osteocalcin signaling influences exercise adaptation and muscle performance.

Adipose Tissue

Research suggested regulation of adiponectin and insulin sensitivity.

Testis

Several studies implicated GPRC6A in testosterone production and male fertility.

Prostate Cancer

The Quarles group reported increased expression of GPRC6A in prostate cancer and proposed links between metabolism and tumor progression.

By 2015, GPRC6A appeared to participate in nearly every major physiological system.

That success would soon generate skepticism.

---

Act V: The Copenhagen Challenge

Scientific fields mature when independent groups test foundational assumptions.

For GPRC6A, the most important challenge came from Hans Bräuner-Osborne's group in Copenhagen.

Influential Paper #5

Jørgensen et al. (2017)

"Genetic Variations in Human GPRC6A Control Cell Surface Expression and Function."

Impact:

• Demonstrated that human GPRC6A differs substantially from rodent GPRC6A.
• Showed that human-specific polymorphisms alter receptor trafficking.
• Raised concerns about translating mouse findings directly to humans.

This paper marked a turning point.

Many earlier discoveries were based on mouse models.

If human GPRC6A behaves differently, how much of the proposed biology applies to humans?

The question remains unresolved.

---

The Most Important Review Ever Written on GPRC6A

Influential Paper #6

Pi, Nishimoto & Quarles (2017)

"GPRC6A: Jack of All Metabolism (or Master of None)."

Impact:

• Summarized nearly a decade of discoveries.
• Explicitly acknowledged the controversies.
• Presented the competing interpretations of the field.
• Became the definitive review for researchers entering GPRC6A biology.

The title itself captured the central dilemma.

Is GPRC6A truly a master metabolic regulator?

Or have researchers attributed too many functions to a single receptor?

---

The Diaz-Franco Synthesis

Influential Paper #7

Diaz-Franco et al. (2019)

"Osteocalcin-GPRC6A: An Update of Its Clinical and Biological Multi-Organic Interactions."

Impact:

• Synthesized evidence across multiple organs.
• Consolidated findings involving brain, muscle, liver, pancreas, testis, and intestine.
• Became a valuable reference for clinicians and endocrinologists.

---

Ranking the Most Influential Research Groups

Tier 1: Field Builders

Min Pi & L. Darryl Quarles

Contributions:

• Metabolism
• Diabetes
• Osteocalcin signaling
• Testosterone signaling
• Prostate cancer
• Endocrine network models

Influence: Extraordinary

Without this group, GPRC6A would likely remain a niche nutrient-sensing receptor.

---

Gerard Karsenty & Patricia Ducy

Contributions:

• Bone endocrinology
• Osteocalcin biology
• Bone-pancreas-testis axis

Influence: Extraordinary

They transformed osteocalcin from a bone marker into a candidate hormone.

---

Tier 2: Critical Evaluators

Hans Bräuner-Osborne Group

Contributions:

• Receptor pharmacology
• Human polymorphisms
• Evolutionary divergence
• Ligand specificity

Influence: High

Provided some of the strongest evidence that human and rodent GPRC6A may differ substantially.

---

Tier 3: Expansionists

Atsushi Mizokami Group

Contributions:

• GLP-1 secretion
• Intestinal signaling
• Glucose homeostasis

Influence: Moderate to High

Extended GPRC6A biology beyond pancreas and bone.

---

Where Does the Field Stand Today?

Twenty years after its discovery, GPRC6A remains scientifically fascinating precisely because the central questions remain unresolved.

Most researchers agree that:

• GPRC6A senses amino acids.
• GPRC6A participates in metabolic regulation.
• Rodent GPRC6A has important physiological functions.

What remains controversial is:

• Whether osteocalcin is a bona fide physiological ligand.
• Whether testosterone directly activates the receptor.
• Whether human GPRC6A functions similarly to rodent GPRC6A.
• Whether GPRC6A is a major therapeutic target or a biological curiosity.

The history of GPRC6A therefore illustrates an important lesson in science.

The most influential discoveries are not always the ones that are immediately accepted.

Sometimes the most influential discoveries are the ones that generate twenty years of productive disagreement.

And by that standard, GPRC6A has been one of the most successful receptors of the modern endocrine era.

Evidence That GPRC6A Is Functional in Buffalo: What a Leydig Cell Study Shows

The question of whether GPRC6A is functional in buffalo is not just a genome-annotation puzzle. It connects directly to reproductive physiology, testosterone biosynthesis, and the emerging idea that bone-derived hormones can talk to the testis.

A 2024 paper in Veterinary Research Communications provides an important buffalo-specific piece of evidence:

“In vitro effects of uncarboxylated osteocalcin on buffalo Leydig cell steroidogenesis.”

The authors are B. S. Bharath Kumar, Smrutirekha Mallick, H. V. Manjunathachar, C. G. Shashank, Ankur Sharma, Dudekula Nagoorvali, Simson Soren, Vyankat Gangadhar Jadhav, and Sujata Pandita. The study was published in Veterinary Research Communications volume 48, pages 1423 to 1433, in 2024, with DOI 10.1007/s11259-024-10320-4.

The paper investigates whether uncarboxylated osteocalcin, abbreviated UcOCN, affects testosterone synthesis in buffalo Leydig cells, and whether the osteocalcin receptor GPRC6A is present in those cells.

The central argument is:

UcOCN → GPRC6A-positive buffalo Leydig cells → steroidogenic gene expression → testosterone production

The paper does not perform a GPRC6A knockdown or receptor-blocking experiment, so it does not prove every step with genetic causality. But it does provide a valuable buffalo-specific evidence stack showing that GPRC6A is present in the right cell type and that the proposed ligand, UcOCN, stimulates the steroidogenic program.

1. The study is directly about buffalo Leydig cells

The first strength of the study is species and cell-type relevance. The authors did not use a mouse model, human cell line, or generic testicular tissue. They isolated Leydig cells from adult Murrah buffalo testes.

The study used testes from buffaloes aged 4 to 6 years, collected from a local abattoir. Leydig cells were isolated by collagenase digestion and enriched using a discontinuous Percoll gradient. The cell band collected between the 30% and 58% Percoll phases was used for downstream characterization and culture.

This matters because a gene can be functional in one species and tissue context but not another. Here, the evidence is anchored in buffalo Leydig cells, the very cells responsible for testosterone production.

2. The authors first establish that they are working with Leydig cells

Before claiming anything about GPRC6A or osteocalcin signaling, the authors needed to show that their cultures actually contained Leydig cells. They did this in several ways.

Flow cytometry, Figure 1

The authors used CYP11A1-FITC staining and flow cytometry to estimate Leydig cell purity. CYP11A1 is a steroidogenic mitochondrial enzyme and a Leydig cell marker.

In Figure 1, panels A to D show forward scatter versus side scatter plots with the main representative cell population gated. Panels E to H show histograms for control and CYP11A1-FITC staining. Panel H separates CYP11A1-positive and CYP11A1-negative populations.

The authors report that immunophenotyping revealed Leydig cell populations ranging from 69% to 73.9% across trials.

That is important because the later testosterone and gene-expression assays are being performed on a Leydig-cell-enriched population, not an uncharacterized testicular soup.

Morphology, Figures 2 and 3

The cells were also followed morphologically during culture.

In Figure 2, the authors show the appearance of buffalo Leydig cells across different days of culture. The cells proliferate in focal colonies after 48 hours, reach 30 to 40% confluence by day 4, and about 70% confluence by days 5 to 6.

In Figure 3, higher magnification shows polygonal, triangular, spindle-shaped, and irregular Leydig cells. The figure also highlights fat droplets in the cytoplasm.

Those cytoplasmic lipid droplets are biologically relevant because Leydig cells use cholesterol and lipid stores as steroidogenic substrate. The cells are not just alive in culture. They look like steroidogenic cells.

3. CYP11A1 staining confirms Leydig cell identity

The next line of evidence comes from immunocytochemistry.

Immunostaining, Figure 4

In Figure 4, the authors stain the cultured cells with a primary antibody against CYP11A1, described in the caption as specific for Leydig cells. Hoechst stains nuclei, FITC marks antibody signal, and the merged image shows CYP11A1-positive Leydig cells.

The negative control omits the primary antibody and shows no CYP11A1 staining.

This is a key control. It reduces the chance that the FITC signal is just nonspecific glow, the kind of fluorescence goblin that haunts cell-biology papers.

The text states that nearly all proliferating cultured cells stained positive for CYP11A1, confirming their Leydig-cell identity.

The evidence so far:

• Flow cytometry shows a Leydig-enriched population.
• Morphology is consistent with Leydig cells.
• CYP11A1 immunostaining confirms steroidogenic Leydig identity.

Only after building this foundation do the authors turn to GPRC6A.

4. GPRC6A protein is detected in buffalo Leydig cells

This is the first direct evidence relevant to GPRC6A functionality.

GPRC6A immunostaining, Figure 5

In Figure 5, the authors stain buffalo Leydig cells with a primary antibody against GPRC6A. The figure includes:

• GPRC6A primary antibody staining
• A control where primary antibody was omitted
• Hoechst nuclear staining
• FITC-labeled secondary antibody images
• Merged Hoechst and FITC images
• 20× magnification
• 100 μm scale bar

The text reports that proliferated Leydig cells tested positive for GPRC6A antibody, suggesting the presence of an osteocalcin receptor.

This is a major buffalo-specific result. It shows that GPRC6A is not only annotated in the genome, but its protein product is detectable in cultured buffalo Leydig cells.

The paper’s wording is cautious but clear: immunostaining confirmed the presence of “GPRC6A receptors.”

This is necessary evidence for functionality. A receptor cannot mediate UcOCN action if it is absent from the relevant cell type.

5. UcOCN stimulates testosterone production in buffalo Leydig cells

The next question is whether GPRC6A-positive buffalo Leydig cells respond to the proposed ligand.

The authors treated cultured buffalo Leydig cells with different concentrations of UcOCN:

• 0 ng/ml
• 1 ng/ml
• 2 ng/ml
• 6 ng/ml
• 12 ng/ml
• 24 ng/ml
• 48 ng/ml

They also used 0.5 ng/ml luteinizing hormone, LH, as a positive control.

After 24 hours, testosterone in the culture medium was extracted and measured using a bovine-specific testosterone ELISA.

Testosterone assay, Figure 6

In Figure 6, testosterone production increases after UcOCN treatment.

The reported mean testosterone concentrations were:

• Control, 0 ng/ml UcOCN: 0.22 ± 0.01 ng/10⁶ cells/24 h
• 1 ng/ml UcOCN: 0.31 ± 0.03
• 2 ng/ml UcOCN: 0.86 ± 0.09
• 6 ng/ml UcOCN: 1.81 ± 0.17
• 12 ng/ml UcOCN: 1.51 ± 0.15
• 24 ng/ml UcOCN: 1.20 ± 0.29
• 48 ng/ml UcOCN: 1.39 ± 0.35
• LH positive control: 1.88 ± 0.24

The strongest UcOCN response occurs at 6 ng/ml, reaching almost the same testosterone output as LH.

The authors describe a “dose-dependent increase” in testosterone concentration with UcOCN supplementation, although the response becomes less consistent at higher doses.

This is a central functional observation. Buffalo Leydig cells that contain GPRC6A respond to UcOCN by increasing testosterone production.

6. UcOCN activates the steroidogenic gene program

Testosterone production is the final output. The authors also asked whether UcOCN activates the machinery that makes testosterone.

They measured mRNA expression of four steroidogenic enzyme genes by quantitative real-time PCR:

• CYP11A1
• CYP17A1
• HSD3β1
• HSD3β6

GAPDH was used as the housekeeping gene. Relative expression was calculated using the 2−ΔΔCT method.

qPCR assay, Figure 7

In Figure 7, the authors compare gene expression in:

• Control Leydig cells
• Cells treated with 6 ng/ml UcOCN
• Cells treated with 0.5 ng/ml LH

UcOCN significantly upregulates all four steroidogenic genes.

The authors report that:

• HSD3β1 increased by about 2.5-fold
• HSD3β6 increased by about 2.5-fold
• CYP11A1 increased by about 2.5-fold
• CYP17A1 increased by about 4-fold

This is powerful because it connects the hormone output to the transcriptional machinery that produces that output.

The logic is clean:

UcOCN treatment increases steroidogenic enzyme transcripts, and testosterone rises.

The paper also notes that the LH-treated cells show a similar gene-expression pattern, suggesting that UcOCN activates a steroidogenic program comparable in direction to a canonical Leydig-cell stimulus.

7. The GPRC6A localization result makes the UcOCN response biologically plausible

The key GPRC6A-specific figure is Figure 5, but its importance becomes clearer when paired with Figures 6 and 7.

Figure 5 says the receptor is present.

Figure 6 says UcOCN increases testosterone.

Figure 7 says UcOCN increases steroidogenic gene expression.

Together, these figures support the following model:

GPRC6A-positive buffalo Leydig cell + UcOCN → increased steroidogenic gene expression → increased testosterone production

The authors make this interpretation in the discussion, arguing that localization of GPRC6A on buffalo Leydig cells establishes osteocalcin’s mode of action.

That is the core evidence for functionality in buffalo.

8. Why the evidence supports GPRC6A functionality

A functional receptor should satisfy several expectations.

Expectation 1: It should be present in the relevant cell type

GPRC6A is detected in buffalo Leydig cells by immunostaining in Figure 5.

Expectation 2: The cell should respond to the receptor’s ligand

UcOCN stimulates testosterone production in Figure 6.

Expectation 3: The response should involve the expected biological pathway

UcOCN increases steroidogenic genes in Figure 7.

Expectation 4: The response should be physiologically meaningful

The output is testosterone, the key Leydig cell steroid hormone.

By these standards, the paper provides a credible argument that GPRC6A is functional in buffalo Leydig cells.

9. What the paper does not prove

A careful interpretation is important.

This paper does not include:

• GPRC6A siRNA knockdown
• GPRC6A knockout
• receptor antagonist treatment
• receptor rescue
• direct UcOCN-GPRC6A binding assay
• cAMP or CREB signaling assay
• comparison of UcOCN response before and after blocking GPRC6A

Therefore, the study does not prove that the testosterone response is completely GPRC6A-dependent.

The strongest safe conclusion is:

Buffalo Leydig cells express GPRC6A, and UcOCN stimulates testosterone production and steroidogenic gene expression in those cells. This supports a functional UcOCN-GPRC6A axis in buffalo, but direct receptor-dependence remains to be tested.

That caveat does not weaken the paper’s value. It simply places the evidence in the right category. The paper is not a receptor-knockdown causality study. It is a buffalo-specific receptor-localization and ligand-response study.

10. Why this matters

For buffalo biology, this paper is important because it moves GPRC6A beyond mere annotation.

It shows that in buffalo Leydig cells:

• the receptor is detectable,
• the cells respond to the receptor’s known ligand,
• steroidogenic genes are induced,
• testosterone production rises,
• the effect resembles the direction of LH stimulation.

That is not a ghost gene. That is a receptor with a plausible physiological job.

The study’s final message is that UcOCN affects testosterone biosynthesis in buffalo Leydig cells and that GPRC6A is positioned as the receptor through which osteocalcin may act.

In short:

GPRC6A in buffalo is not just a predicted GPCR sitting quietly in the genome. In buffalo Leydig cells, it appears as part of a bone-testis signaling axis that can stimulate steroidogenesis.

GPRC6A Is Functional in the Cow: A Detailed Analysis of the Evidence from Jin et al. (2022)

One of the recurring challenges in genome annotation is distinguishing between genes that merely exist in the genome and genes that actively participate in physiological processes. For the bovine receptor GPRC6A, an important question is whether it functions as a genuine signaling receptor in cattle or whether it is simply a conserved but biologically irrelevant genomic relic.

A compelling answer comes from the 2022 study by Xin Jin, Zhen Zhen, Zhaoxiong Wang, Xuejun Gao, and Meng Li, entitled:

"GPRC6A is a key mediator of palmitic acid regulation of lipid synthesis in bovine mammary epithelial cells."

Published in Cell Biology International, this study uses primary bovine mammary epithelial cells (BMECs), pharmacological inhibition, receptor knockdown, pathway analysis, and lipid-synthesis assays to test whether GPRC6A functions in bovine cells.

The conclusion is remarkably clear:

GPRC6A is required for palmitic acid signaling that stimulates milk-fat synthesis in bovine mammary epithelial cells.

The evidence supporting this conclusion is extensive and proceeds through a series of increasingly rigorous experiments.

The biological question

Milk fat is composed primarily of triglycerides and represents one of the most energetically important components of milk.

The authors begin from the observation that:

"Fatty acids can promote lipid synthesis in the mammary gland via stimulating lipogenic gene expression."

However, the molecular mechanism linking extracellular fatty acids to intracellular lipogenic pathways remained unclear.

The central hypothesis tested in the paper is:

Palmitic acid → GPRC6A → PI3K / PKCα → SREBP-1c → Lipid synthesis

The study therefore investigates whether GPRC6A acts as the upstream receptor connecting extracellular palmitic acid to milk-fat synthesis.

---

Evidence 1: Palmitic acid stimulates lipid synthesis in bovine mammary epithelial cells

Before discussing GPRC6A, the authors first establish the biological phenomenon itself.

Primary BMECs were treated with:

• 0 μM PA
• 50 μM PA
• 100 μM PA
• 150 μM PA
• 200 μM PA

Lipid synthesis was measured using two independent assays:

Assay 1: Triglyceride secretion

Triglycerides secreted into the culture medium were quantified using a triglyceride detection kit.

Assay 2: Lipid droplet formation

Cells were stained with BODIPY 493/503 and examined by confocal microscopy.

Figure 1

The authors report:

"TGs secreted by cells and LDs formation in cells were both increased, peaked at 100 μM, then gradually decreased."

This establishes a dose-response relationship between palmitic acid and lipid synthesis.

Most importantly:

• Lipid droplets increase.
• Triglyceride secretion increases.
• Both peak at 100 μM PA.

Thus, the system exhibits a measurable biological output that can later be linked to GPRC6A.

---

Evidence 2: Palmitic acid activates lipogenic signaling pathways

The next question is whether palmitic acid activates molecular regulators of lipid synthesis.

The authors measured:

• Full-length SREBP-1c (fSREBP-1c)
• Mature nuclear SREBP-1c (nSREBP-1c)
• PKCα phosphorylation

using Western blotting.

Figure 2

The paper reports:

"PA dose-dependently stimulated protein levels of fSREBP-1c and nSREBP-1c, and PKCα phosphorylation."

This is important because SREBP-1c is one of the master transcription factors controlling lipogenesis.

The appearance of nuclear SREBP-1c indicates activation of the lipogenic program rather than simple protein accumulation.

At this stage the pathway is:

PA → SREBP-1c activation → Lipid synthesis

but the receptor remains unidentified.

---

Evidence 3: PI3K is required for palmitic-acid signaling

To determine whether PI3K lies downstream of the receptor, the authors inhibited PI3K using LY294002.

Experimental design

Cells were treated with:

• 100 μM PA
• 15 μM LY294002

Figure 3

The paper reports:

"PI3K inhibition totally blocked PA-stimulated protein levels of fSREBP-1c and nSREBP-1c and TGs secretion by cells."

The authors further write:

"These data demonstrate that PI3K is a key mediator of the induction of PA on SREBP-1c expression and subsequent maturation."

This experiment establishes PI3K as a necessary signaling intermediate.

---

Evidence 4: PKCα controls SREBP-1c maturation

The authors next investigated PKCα.

PKCα was knocked down using siRNA.

Figure 4

The results are striking.

The authors state:

"PKCα knockdown only partially decreased the stimulation of PA on fSREBP-1c protein level, but almost totally abolished the stimulation of PA on nSREBP-1c protein level and TG secretion."

In other words:

• SREBP-1c expression still occurs.
• SREBP-1c maturation does not.

This places PKCα specifically at the maturation step.

The pathway now becomes:

PA → PI3K → PKCα → nSREBP-1c → Lipid synthesis

---

Evidence 5: Eliminating GPR120 as the receptor

One of the strongest features of this paper is that the authors do not simply claim GPRC6A involvement.

They first test a competing hypothesis.

GPR120 is a well-known fatty-acid receptor and would be the obvious candidate.

The authors therefore performed:

GPR120 knockdown

using siRNA.

Figure 5

The results were negative.

The authors write:

"GPR120 knockdown did not affect PA-stimulated protein levels of fSREBP-1c and nSREBP-1c."

They conclude:

"GPR120 might not participate in PA signaling to SREBP-1c expression and maturation in BMECs."

This experiment is extremely important.

Rather than merely showing GPRC6A involvement, the authors demonstrate that another plausible receptor cannot explain the observed signaling.

---

Evidence 6: GPRC6A knockdown abolishes pathway activation

This is the centerpiece of the paper.

The authors directly knocked down GPRC6A using siRNA.

Figure 6

Following GPRC6A knockdown they measured:

• PI3K phosphorylation
• PKCα phosphorylation
• fSREBP-1c
• nSREBP-1c
• Triglyceride secretion

The results are dramatic.

The authors state:

"GPRC6A knockdown almost totally blocked the stimulation of PA on PI3K activation and PKCα activation."

They further report:

"GPRC6A knockdown also significantly decreased PA-stimulated protein levels of fSREBP-1c and nSREBP-1c and TG secretion by cells."

Finally they conclude:

"These data demonstrate that GPRC6A is a key mediator of the stimulation of PA on the PI3K/PKCα-SREBP-1c signaling."

This is the strongest evidence for functionality in the paper.

Removing GPRC6A eliminates:

• PI3K activation
• PKCα activation
• SREBP-1c expression
• SREBP-1c maturation
• Triglyceride production

A receptor that is dispensable would not produce this phenotype.

---

Evidence 7: Palmitic acid increases GPRC6A abundance

The authors next ask whether palmitic acid influences the receptor itself.

Assay

Western blotting for GPRC6A.

Figure 7A-B

The paper reports:

"PA dose-dependently affected the protein level of GPRC6A in BMECs, with the most stimulatory effect at 100 μM."

This is notable because the concentration producing maximal lipid synthesis is also the concentration producing maximal GPRC6A expression.

The receptor responds in parallel with the biological phenotype.

---

Evidence 8: Palmitic acid promotes plasma-membrane localization of GPRC6A

Expression alone does not guarantee functionality.

The receptor must also be located where it can sense extracellular ligands.

The authors therefore performed:

Immunofluorescence microscopy

using anti-GPRC6A antibodies.

Figure 7C-D

The paper reports:

"Immunofluorescence observation detected that PA stimulated plasma membrane localization of GPRC6A."

The effect again:

"peaked at 100 μM."

This is one of the most convincing observations in the paper.

A GPCR must reside at the plasma membrane to function as an extracellular sensor.

The increase in membrane-localized GPRC6A strongly supports receptor activation and physiological relevance.

---

The authors' own interpretation

The Discussion section is unusually direct.

The authors write:

"GPRC6A is required for PA to trigger PI3K and PKCα activation and subsequent SREBP-1c expression and maturation."

They further state:

"PA promoted GPRC6A expression and plasma membrane localization, suggesting that GPRC6A might be activated by PA stimulation."

Finally:

"GPRC6A controls lipid synthesis via the PI3K/PKCα-SREBP-1c signaling pathways."

And perhaps most importantly:

"To our knowledge, this is the first report that a FA functions in lipid synthesis via the GPRC6A signaling."

---

What does this prove?

This paper demonstrates that bovine GPRC6A:

1. Is expressed in primary bovine mammary epithelial cells.
2. Is regulated by palmitic acid.
3. Relocates to the plasma membrane in response to palmitic acid.
4. Is required for PI3K activation.
5. Is required for PKCα activation.
6. Is required for SREBP-1c expression.
7. Is required for SREBP-1c maturation.
8. Is required for triglyceride synthesis.

Together, these findings provide a compelling case that GPRC6A is a biologically functional receptor in cattle.

The paper does not directly prove that palmitic acid physically binds GPRC6A. The authors explicitly acknowledge this limitation, writing:

"It is not known and needs to be explored in the future study whether GPRC6A is a receptor of PA."

Nevertheless, receptor functionality does not depend solely on direct ligand-binding assays. A receptor whose loss abolishes signaling and phenotype is clearly functioning within the pathway.

From a bovine genomics perspective, this paper provides strong experimental evidence that GPRC6A is not simply an annotated gene. It is an active signaling component controlling lipid synthesis in bovine mammary epithelial cells through the PI3K-PKCα-SREBP-1c axis.

Evidence That GPRC6A Is Functional in Cattle: What a Bovine Mammary Cell Study Shows

A recurring question in livestock genomics is whether a gene that exists in the cow genome is actually functional in cow biology. For GPRC6A, a G protein-coupled receptor known in other species as a nutrient and amino-acid sensor, one useful piece of evidence comes from a 2019 paper in the Journal of Agricultural and Food Chemistry:

“Lysine Enhances the Stimulation of Fatty Acids on Milk Fat Synthesis via the GPRC6A-PI3K-FABP5 Signaling in Bovine Mammary Epithelial Cells.”

The study was authored by Xueying Li, Ping Li, Lulu Wang, Minghui Zhang, and Xuejun Gao. Xueying Li and Xuejun Gao were affiliated with the School of Animal Science, Yangtze University, Jingzhou, China, while Ping Li, Lulu Wang, and Minghui Zhang were affiliated with The Key Laboratory of Dairy Science of Education Ministry, Northeast Agricultural University, Harbin, China. The paper appeared in Journal of Agricultural and Food Chemistry in 2019, volume 67, pages 7005 to 7015, with DOI 10.1021/acs.jafc.9b02160.

The central claim of the paper is that lysine promotes milk-fat synthesis in bovine mammary epithelial cells, BMECs, through a pathway involving:

GPRC6A → PI3K → FABP5 → SREBP-1c → milk-fat synthesis

That pathway is not just decorative biochemistry. The authors test several rungs of the ladder: receptor abundance, receptor localization, pathway activation, knockdown, pharmacological inhibition, and lipid output. Together, these experiments make a strong argument that GPRC6A is functional in bovine mammary epithelial cells.

1. The study begins with primary bovine cells, not a distant surrogate system

The model system matters. This was not a human cell line with bovine gene names painted onto it. The authors used primary bovine mammary epithelial cells isolated from Holstein dairy cows at mid-lactation. They state that BMECs were isolated from mammary gland tissues of Holstein dairy cows and purified from fibroblasts, with epithelial identity confirmed using cytokeratin-18.

This is important because the functional question is cow-specific. If GPRC6A responds to lysine in bovine mammary epithelial cells, then the evidence is directly relevant to cattle lactation biology.

The experimental setup used several treatments:

• Lysine at 0, 0.35, 0.70, 1.05, and 1.40 mM
• Fatty acids, FAs, as a mixture of 100 μM palmitic acid plus 100 μM oleic acid
• PI3K inhibition using LY294002 at 15 μM
• GPRC6A knockdown using siRNA
• FABP5 knockdown using siRNA

This gives the paper a nice causal skeleton: stimulate the system, block the system, knock down the receptor, then ask whether the phenotype survives.

2. GPRC6A is present as a protein in bovine mammary epithelial cells

A gene cannot function through its protein product unless that protein is actually made. The authors tested GPRC6A protein abundance by Western blotting.

In Figure 8A and 8B, BMECs were treated with different lysine concentrations, and GPRC6A protein was measured. The authors report that lysine increased GPRC6A protein up to 0.70 mM, after which the signal declined at higher lysine concentrations.

A key sentence from the Results section says that at low lysine concentrations, lysine “dose-dependently increased the protein level of GPRC6A,” while higher concentrations caused a decrease.

This is the first evidence of functionality: the receptor is not merely predicted from the genome. It is detected as a protein in bovine cells, and its abundance responds to lysine.

Figure detail:

• Figure 8A shows the GPRC6A Western blot.
• Figure 8B quantifies GPRC6A relative protein levels.
• The strongest signal is around 0.70 mM lysine.
• The response is dose-dependent rather than flat background noise.

That dose response is biologically meaningful. It suggests that lysine is not simply present in the medium as a nutrient brick, but is connected to a signaling response involving GPRC6A.

3. GPRC6A localizes to the plasma membrane, where a GPCR should be

For a GPCR, localization is everything. A receptor that never reaches the plasma membrane is a receptor locked in the pantry. GPRC6A is expected to sense extracellular ligands, so its presence at the cell surface is a crucial piece of functional evidence.

The authors tested localization using immunofluorescence staining with an anti-GPRC6A antibody. Their methods describe staining with GPRC6A antibody ab90677, followed by FITC-conjugated secondary antibody, DAPI nuclear staining, confocal microscopy, and ImageJ quantification of GPRC6A signal.

In Figure 8C, GPRC6A appears as a green ring around the cell. The authors describe the signal as being in the “outer circle of the cell,” forming a “thin and circular structure.” They interpret this as plasma membrane localization.

Figure detail:

• Figure 8C shows GPRC6A immunofluorescence in green and DAPI in blue.
• The green signal forms a membrane-like ring.
• Figure 8D quantifies GPRC6A fluorescence per cell.
• The maximum membrane-associated signal occurs at 0.70 mM lysine.

This matters because membrane localization is a functional checkpoint for GPCR biology. The receptor is positioned where it can plausibly detect extracellular lysine or related signals.

4. Lysine activates the downstream lipid-synthesis program

Before asking whether GPRC6A is required, the authors first establish that lysine changes the phenotype of BMECs.

They measure several outputs of milk-fat synthesis:

• SREBP-1c protein expression by Western blot
• nSREBP-1c maturation by Western blot
• Triglyceride secretion using a TG assay kit
• Lipid droplet formation using BODIPY staining
• ImageJ quantification of lipid droplets

In Figure 2, lysine alone increases SREBP-1c, mature nSREBP-1c, triglyceride secretion, and lipid droplet formation, again peaking around 0.70 mM.

In Figure 3, the authors repeat the analysis in the presence of fatty acids. Here the effect is stronger. They report that at 0.70 mM lysine plus FAs, triglyceride content increased by 85.9%, and lipid droplet formation increased by 428.6%, compared with control.

This is the second layer of functionality: lysine produces a real cellular output linked to milk-fat synthesis. The cell is not just flickering a single signaling protein. It is changing lipid metabolism.

5. Lysine and fatty acids cooperate, and FABP5 enters the pathway

The paper then asks whether the lysine effect is connected to fatty-acid handling. The answer is yes, through FABP5, a fatty-acid-binding protein.

In Figure 4, cells were treated with lysine, fatty acids, or lysine plus fatty acids. The lysine-plus-fatty-acid group shows the strongest induction of:

• SREBP-1c
• nSREBP-1c
• FABP5
• TG secretion
• lipid droplet formation

The authors write that SREBP-1c expression and maturation, along with FABP5 expression, were “markedly increased” in cells treated with lysine together with fatty acids.

Figure detail:

• Figure 4A shows Western blots for SREBP-1c, nSREBP-1c, FABP5, and β-actin.
• Figure 4B to 4D quantify these protein changes.
• Figure 4E measures triglyceride secretion.
• Figure 4F and 4G show and quantify lipid droplets.

This supports the model that lysine does not act in isolation. It enhances a fatty-acid-dependent milk-fat synthesis program, with FABP5 serving as a lipid-handling mediator.

6. FABP5 knockdown shows that the lipid-handling branch is required

Association is not causation, so the authors knocked down FABP5 using siRNA.

In Figure 5, FABP5 knockdown strongly reduces FABP5 protein and prevents the lysine-induced increase in SREBP-1c and nSREBP-1c. The authors state that FABP5 knockdown “almost totally abolished” lysine-stimulated SREBP-1c expression and maturation.

Figure detail:

• Figure 5A shows Western blots after FABP5 knockdown.
• Figure 5B confirms reduced FABP5 protein.
• Figure 5C shows loss of SREBP-1c induction.
• Figure 5D shows loss of nSREBP-1c maturation.

This is not direct proof of GPRC6A yet, but it proves that the downstream lipid arm of the pathway is functional and necessary. If GPRC6A is upstream of FABP5, then loss of GPRC6A should collapse the same pathway. That is exactly what the authors test next.

7. PI3K inhibition blocks lysine signaling downstream

The proposed pathway runs through PI3K, so the authors used the PI3K inhibitor LY294002.

In Figure 6, cells were treated with LY294002, lysine, and fatty acids. The authors measured p-AKT/AKT as a readout of PI3K pathway inhibition, along with FABP5, SREBP-1c, and nSREBP-1c.

They report that PI3K inhibition “totally abolished Lys-stimulated” FABP5 expression and SREBP-1c expression/maturation.

Figure detail:

• Figure 6A shows Western blots.
• Figure 6B confirms pathway inhibition using p-AKT/AKT.
• Figure 6C shows reduced FABP5.
• Figure 6D shows reduced SREBP-1c.
• Figure 6E shows reduced nSREBP-1c.

This experiment establishes PI3K as a required signaling bridge between the upstream receptor system and the downstream lipid program. The pathway is no longer just a string of names. It has a pharmacological weak point.

8. The strongest evidence: GPRC6A knockdown collapses PI3K signaling and downstream lipid regulators

The most important experiment in the paper is Figure 7.

Here, the authors directly knock down GPRC6A with siRNA and ask whether lysine can still activate the proposed pathway. The answer is no.

The authors state that GPRC6A knockdown “totally abolished Lys-stimulated PI3K phosphorylation.” They also report loss of FABP5 expression, SREBP-1c expression, and SREBP-1c maturation.

Figure detail:

• Figure 7A shows Western blots for GPRC6A, SREBP-1c, nSREBP-1c, FABP5, PI3K, p-PI3K, and β-actin.
• Figure 7B confirms GPRC6A knockdown.
• Figure 7C shows collapse of p-PI3K/PI3K.
• Figure 7D shows loss of FABP5 induction.
• Figure 7E shows loss of SREBP-1c induction.
• Figure 7F shows loss of nSREBP-1c maturation.

This is the functional centerpiece. If GPRC6A were merely present but irrelevant, knocking it down would not erase the lysine response. Instead, the pathway loses its upstream spark.

The authors summarize this directly: lysine stimulates PI3K and downstream signaling in a GPRC6A-dependent manner.

That is strong evidence for functionality in cattle cells.

9. The evidence supports function, but not every possible mechanism is proven

The paper makes a persuasive case that bovine GPRC6A is functional in BMECs. It shows:

1. GPRC6A protein is present.
2. GPRC6A abundance responds to lysine.
3. GPRC6A localizes to the plasma membrane.
4. Lysine activates PI3K signaling.
5. Lysine activates FABP5 and SREBP-1c.
6. Lysine increases triglyceride secretion and lipid droplets.
7. PI3K inhibition blocks downstream signaling.
8. FABP5 knockdown blocks SREBP-1c activation.
9. GPRC6A knockdown collapses PI3K phosphorylation and downstream signaling.

But there is one important caveat: the study does not directly prove that lysine physically binds bovine GPRC6A. There is no ligand-binding assay, receptor rescue experiment, receptor mutant analysis, calcium flux assay, cAMP assay, or β-arrestin recruitment assay.

So the careful conclusion is:

This paper shows that GPRC6A is functionally required for lysine-stimulated PI3K-FABP5-SREBP-1c signaling and milk-fat synthesis markers in bovine mammary epithelial cells. It strongly supports GPRC6A functionality in cattle, although it does not directly demonstrate lysine-GPRC6A binding.

10. Why this matters for the cow genome

For genome annotation, the question is often whether a gene is merely predicted or whether it has biological life. In this paper, GPRC6A passes several functionality tests.

It is expressed.
It is translated.
It reaches the plasma membrane.
It responds to lysine.
Its knockdown destroys a signaling response.
Its pathway connects to a biologically meaningful bovine phenotype: milk-fat synthesis.

That is a substantial evidence stack. Not perfect, but far beyond annotation-by-guesswork.

In short, GPRC6A in cow is not just a genomic wallflower. In bovine mammary epithelial cells, it behaves like a working receptor in a nutrient-sensitive signaling pathway controlling lipid synthesis.